RNA interference

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

Retrieved on: 
среда, мая 15, 2024
Patient, TNNT2, FSHD, Investment, NHP, FDA, IND, Safety, Sale, Duchenne, Research, CMC, RNA interference, Solid, Duchenne muscular dystrophy, BLA, Facioscapulohumeral muscular dystrophy, Therapy, CPVT, Pharmaceutical industry

CHARLESTOWN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • CHARLESTOWN, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a business update.
  • We anticipate providing a topline readout of safety, microdystrophin expression and functional benefit by year end,” said Bo Cumbo, President and CEO, Solid Biosciences.
  • Initial safety, microdystrophin expression and functional benefit data from the first 3-4 patients enrolled in the trial is expected by the fourth quarter of 2024.
  • Net loss for the first quarter of 2024 was $24.3 million, compared to $30.1 million for the first quarter of 2023.

Bio-Path Holdings Reports First Quarter 2024 Financial Results

Retrieved on: 
среда, мая 15, 2024
Lymphoma, Patient, Patent, Clinical trial, FDA, Safety, Sale, Call, CLL, AML, Cancer, RNA interference, ATM, Research, Holding, Acute myeloid leukemia, Pharmaceutical industry

HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.

Key Points: 
  • ET
    HOUSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the first quarter ended March 31, 2024 and provided an update on recent corporate developments.
  • These achievements leave us well positioned for continued progress throughout the balance of the year.”
    Expanded Global Patent Portfolio.
  • As of March 31, 2024, the Company had cash of $0.2 million, compared to $1.1 million as of December 31, 2023.
  • ET to review these first quarter 2024 financial results and to provide a general update on the Company.

Atalanta Therapeutics Expands Executive Team with Appointments of Chief Medical Officer and Chief Financial Officer

Retrieved on: 
среда, мая 22, 2024
Biotechnology, Pharmaceutical, Health, Neurology, PwC, Patient, Atalanta, University, RNA interference, CFO, FTD, IND, Therapy, Drug development, Weill Cornell Medical Center, DSM-IV codes, Weill Cornell Medicine, Growth, Research, NewYork-Presbyterian Hospital, CNS, Chemical engineering, Accounting, RNA, Frontotemporal dementia, Georgetown University, Pharmaceutical industry

Atalanta Therapeutics , a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the expansion of its executive team with the appointments of Serena Hung, M.D., as chief medical officer, and Jeffrey Young as chief financial officer.

Key Points: 
  • Atalanta Therapeutics , a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the expansion of its executive team with the appointments of Serena Hung, M.D., as chief medical officer, and Jeffrey Young as chief financial officer.
  • “We are thrilled to welcome Jeffrey and Serena to Atalanta’s executive team as we prepare for our next phase of growth in building the leading CNS RNAi company,” said Alicia Secor, Atalanta’s president and chief executive officer.
  • “Atalanta’s discovery efforts utilize our best-in-class di-siRNA platform and have generated a robust portfolio of 14 current programs across our wholly-owned and partnered pipelines.
  • Mr. Young joins Atalanta with more than 25 years of experience in finance and capital markets at life sciences and medical technology companies.

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Retrieved on: 
понедельник, мая 20, 2024
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Molecule, Lung, Patient, Arrowhead, Asthma, FVC, Pharmacodynamics, NHV, Safety, RAGE, Conference, Serum, American Thoracic Society, H5N1, TSLP, BALF, Interim, RNA interference, ATS, ARO, Gastric lavage, DLCO, FEV1, Pharmaceutical industry

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference.

Key Points: 
  • Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that new interim clinical data on ARO-RAGE, an investigational RNAi-based medicine for the treatment of inflammatory lung diseases, such as asthma, were presented at the American Thoracic Society (ATS) 2024 International Conference.
  • “These results underscore the potential of our proprietary TRiMTM platform to enable us to develop impactful new therapies to potentially treat multiple pulmonary diseases with significant unmet needs.
  • Arrowhead also presented preclinical data on two additional lung targeted programs that utilize the company’s proprietary Targeted RNAi Molecule (TRiMTM) platform.
  • ARO-IAV is designed to silence expression of highly conserved influenza A viruses, including the highly pathogenic avian influenza virus (H5N1).

Whitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize Value

Retrieved on: 
пятница, мая 17, 2024
Professional Services, Health, Infectious Diseases, Finance, Pharmaceutical, Biotechnology, Moderna, HBsAg, Partnership, Arrowhead, Arbutus Biopharma, Special, Patent, Johnson & Johnson, GSK, Vaccine, Congress, COVID, RNA, District court, Therapy, Probability, Hepatitis, Retirement, Letter, Arrowhead Pharmaceuticals, Sale, HBV, BioNTech, GSK plc, ATM, PD-L1, Hepatitis B, LNP, Clinical trial, Interim, Roivant Sciences, Patient, RNA interference, EASL, Moderna COVID-19 vaccine, Combo, Janssen Pharmaceuticals, Pharmaceutical industry

Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published an open letter to shareholders outlining its views of the best paths forward to maximize value.

Key Points: 
  • Whitefort Capital Management, LP (together with its affiliates, “Whitefort Capital,” “us” or “we”), which is a long-term investor and the second largest shareholder of Arbutus Biopharma Corp. (NASDAQ: ABUS) (“Arbutus” or the “Company”) with an ownership interest of approximately 6.8% of the Company’s outstanding shares, today published an open letter to shareholders outlining its views of the best paths forward to maximize value.
  • Whitefort is a long-term investor in Arbutus, having continuously held shares since October 2022.
  • We also want to ensure that the Board of Directors (the “Board”) and our fellow shareholders understand the urgency of these issues.
  • However, we believe that Arbutus should firmly commit to cease any further share issuances for the foreseeable future, including under the ATM program.

JNJ-73763989 (JNJ-6379) for Chronic Hepatitis B in 6MM: Market Size, Forecasts, and Emerging Insight 2019-2023 & 2024-2032 - ResearchAndMarkets.com

Retrieved on: 
пятница, мая 17, 2024
Infectious Diseases, Pharmaceutical, Health, Clinical Trials, CccDNA, Patient, DNA, SWOT, Clinical trial, Arrowhead Pharmaceuticals, HBV, Janssen Pharmaceuticals, DDI, Research, Hepatitis, RNA interference, EU4, Vaccine

"JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets.

Key Points: 
  • "JNJ-73763989 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about JNJ-73763989 for chronic hepatitis B in the six major markets.
  • Other emerging products for chronic hepatitis B are expected to give tough market competition to JNJ-73763989 and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • What are the other emerging products available and how are these giving competition to JNJ-73763989 for chronic hepatitis B?
  • Which are the late-stage emerging therapies under development for the treatment of chronic hepatitis B?

FMC Corporation announces multi-year collaboration with AgroSpheres

Retrieved on: 
четверг, мая 9, 2024
Crop protection, RNA, Partnership, RNA interference, Research, Biotechnology, Insecticide, FMC, FMC Corporation, Vaccine

FMC Corporation (NYSE:FMC), a leading global agricultural sciences company, today announced a research agreement with AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health.

Key Points: 
  • FMC Corporation (NYSE:FMC), a leading global agricultural sciences company, today announced a research agreement with AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and crop health.
  • In 2023, FMC Ventures invested in AgroSpheres, a startup developing biodegradable micro-encapsulation technology to improve the delivery, stability and efficacy of biological crop protection products based on RNA interference (RNAi) technology.
  • "Our research agreement with AgroSpheres marks a significant milestone in FMC's commitment to advancing sustainable agriculture through innovation," said Dr. Seva Rostovtsev, FMC executive vice president and chief technology officer.
  • AgroSpheres' patented AgriCell manufacturing technology allows for the expression of a wide array of RNA molecules while yielding consistent results.

Kate Therapeutics Unveils Platform and Pipeline Progress at American Society of Gene & Cell Therapy 2024 Annual Meeting

Retrieved on: 
четверг, мая 9, 2024
Mortality, FDA, University, Facioscapulohumeral muscular dystrophy, Mouse, RNA interference, Safety, Tissue, Heart, Animal, Death, MD, Primate, Cell, Duchenne, Science, Disease, Rockefeller University, Patient, Liver, Society, Gene, X-linked myotubular myopathy, Pediatrics, Gene expression, Judgement, Duchenne muscular dystrophy, Capsid, Annual general meeting, SAN, Muscular dystrophy, Vaccine

SAN DIEGO, May 9, 2024 /PRNewswire/ -- Kate Therapeutics Inc. ("KateTx"), a next-generation gene therapy company, will present detailed preclinical efficacy and safety results on its pipeline and platform at the American Society of Gene and Cell Therapy (ASGCT) 2024 Annual Meeting being held May 7-11, 2024, in Baltimore, MD and virtually. The results support the best-in-class potential of KateTx's newest generation of skeletal muscle- and heart-targeted, liver de-targeted engineered MyoAAV capsids and gene regulation technology to treat Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and other devastating genetic skeletal muscle and heart diseases.

Key Points: 
  • KateTx remains on track to select development candidates for additional muscle and cardiac programs in the near term.
  • "KateTx has made significant advances over the past 12 months," said Kevin Forrest, Ph.D., co-founder, president and CEO of KateTx.
  • KateTx's results show the potential to give a one-time gene therapy that potently suppresses DUX4 whenever it is expressed in skeletal muscles.
  • In vitro, the company's MyoAAV-LD mediated RNAi gene therapy candidate showed potent knockdown of DUX4 in FSHD patient myotubes with no off-target effects.

e-therapeutics plc shares now trading on JP Jenkins

Retrieved on: 
пятница, мая 10, 2024
RNA interference, Commercial, AIM, ETX, Galapagos NV, Automation, Appointment, Novo Nordisk, Companies House, Biology, Drug development, Drug discovery, Therapy, MASH, Pharmaceutical industry

JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.

Key Points: 
  • JP Jenkins provides a share trading venue for unlisted or unquoted assets in companies, enabling shareholders and prospective investors to buy and sell equity on a matched bargain basis.
  • JP Jenkins is a trading name of InfinitX Limited and Appointed Representative of Prosper Capital LLP (FRN453007).
  • The indicative pricing for the ordinary shares (ISIN: GB00B2823H99), as well as the transaction history, will be available on the JP Jenkins website at (https://jpjenkins.com/company/e-therapeutics-plc/).
  • Veronika Oswald, Commercial Director of JP Jenkins said: “ETX’s transition from AIM to the JP Jenkins venue marks a pivotal milestone in our mission to enhance accessibility and liquidity for their shareholders and investors.

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

Retrieved on: 
среда, мая 8, 2024
RNA interference

ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.

Key Points: 
  • ET to report financial results for the first quarter ended March 31, 2024 and to provide a business overview.
  • To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time.
  • A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com .
  • An archived webcast will be available on the Bio-Path website approximately two hours after the event.